glp 1 agonist and dementia Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders A new Annals for Educators

Initial Treatment Phase: During this time, its important to keep an eye on vitamin B12 levels and symptoms

doi: 10.1186/s12974-024-03116-5 17 HegdekarN.SarkarC.BustosS.RitzelR

Semaglutide (Wegovy) works by targeting one receptor to help control appetite and blood sugar, while Tirzepatide (Mounjaro) targets two receptors, which can lead to potentially greater weight loss results in some patients

It inhibits the production of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12), modulates the polarization of macrophages towards the M2 (anti-inflammatory) phenotype, and stimulates collagen production in models of pulmonary and cutaneous fibrosis

Key takeaways CagriSema combines semaglutide 2.4 mg (a GLP-1 agonist) and cagrilintide 2.4 mg (an amylin analogue) in a single weekly injection

Glycine supplements are generally considered safe